TY - JOUR
T1 - Video-assisted thoracoscopic lobectomy is associated with greater recurrence-free survival than stereotactic body radiotherapy for clinical stage I lung cancer
AU - Cornwell, Lorraine D.
AU - Echeverria, Alfredo E.
AU - Samuelian, Jason
AU - Mayor, Jessica
AU - Casal, Roberto F.
AU - Bakaeen, Faisal G.
AU - Omer, Shuab
AU - Preventza, Ourania
AU - Mai, Weiyuan
AU - Chen, George
AU - Simpson, Katherine H.
AU - Moghanaki, Drew
AU - Zhu, Angela W.
N1 - Publisher Copyright:
© 2017
PY - 2018/1
Y1 - 2018/1
N2 - Objective Stereotactic body radiotherapy is the standard treatment for medically inoperable early-stage non–small cell lung cancer. Recent data suggest that in operable patients, stereotactic body radiotherapy produces outcomes comparable to those of surgical resection. In veterans with early non–small cell lung cancer, we compared the outcomes of stereotactic body radiotherapy and video-assisted thoracoscopic lobectomy. Methods We retrospectively reviewed data from 183 patients (94.0% male) with clinical stage I non–small cell lung cancer who underwent stereotactic body radiotherapy (n = 56) or video-assisted thoracoscopic lobectomy (n = 127) from 2009 to 2014. Propensity matching was used to produce more comparable groups. Primary end points were tumor control and overall, recurrence-free, and lung-cancer–specific survival, as estimated by Kaplan–Meier actuarial analysis. Multivariable analysis was used to identify independent predictors. Results In the overall cohort, the patients who received stereotactic body radiotherapy were older than the patients who received video-assisted thoracoscopic lobectomy (median age, 79.5 vs 64 years) and had more comorbidities. In the 37 propensity-matched pairs, the 3-year actuarial tumor control rate was 54.3% after stereotactic body radiotherapy and 90.6% after video-assisted thoracoscopic lobectomy (P =.0038). Actuarial lung cancer–specific 3-year survival was 78.1% (stereotactic body radiotherapy) versus 93.6% (video-assisted thoracoscopic lobectomy) (P =.055). One-year overall, 3-year overall, and 3-year recurrence-free survivals were 89.2%, 52.9%, and 38.5% after stereotactic body radiotherapy and 94.6%, 85.7%, and 82.8% after video-assisted thoracoscopic lobectomy (P <.005 for all), respectively. In multivariable analysis, stereotactic body radiotherapy independently predicted recurrence and poorer survival. Conclusions In veteran patients with early-stage non–small cell lung cancer, video-assisted thoracoscopic lobectomy resulted in better disease control and survival than stereotactic body radiotherapy. Although prior reports suggest that stereotactic body radiotherapy is a suitable alternative to surgery in early-stage lung cancer, a prospective randomized trial is needed. Nevertheless, stereotactic body radiotherapy remains a suitable option for medically inoperable patients.
AB - Objective Stereotactic body radiotherapy is the standard treatment for medically inoperable early-stage non–small cell lung cancer. Recent data suggest that in operable patients, stereotactic body radiotherapy produces outcomes comparable to those of surgical resection. In veterans with early non–small cell lung cancer, we compared the outcomes of stereotactic body radiotherapy and video-assisted thoracoscopic lobectomy. Methods We retrospectively reviewed data from 183 patients (94.0% male) with clinical stage I non–small cell lung cancer who underwent stereotactic body radiotherapy (n = 56) or video-assisted thoracoscopic lobectomy (n = 127) from 2009 to 2014. Propensity matching was used to produce more comparable groups. Primary end points were tumor control and overall, recurrence-free, and lung-cancer–specific survival, as estimated by Kaplan–Meier actuarial analysis. Multivariable analysis was used to identify independent predictors. Results In the overall cohort, the patients who received stereotactic body radiotherapy were older than the patients who received video-assisted thoracoscopic lobectomy (median age, 79.5 vs 64 years) and had more comorbidities. In the 37 propensity-matched pairs, the 3-year actuarial tumor control rate was 54.3% after stereotactic body radiotherapy and 90.6% after video-assisted thoracoscopic lobectomy (P =.0038). Actuarial lung cancer–specific 3-year survival was 78.1% (stereotactic body radiotherapy) versus 93.6% (video-assisted thoracoscopic lobectomy) (P =.055). One-year overall, 3-year overall, and 3-year recurrence-free survivals were 89.2%, 52.9%, and 38.5% after stereotactic body radiotherapy and 94.6%, 85.7%, and 82.8% after video-assisted thoracoscopic lobectomy (P <.005 for all), respectively. In multivariable analysis, stereotactic body radiotherapy independently predicted recurrence and poorer survival. Conclusions In veteran patients with early-stage non–small cell lung cancer, video-assisted thoracoscopic lobectomy resulted in better disease control and survival than stereotactic body radiotherapy. Although prior reports suggest that stereotactic body radiotherapy is a suitable alternative to surgery in early-stage lung cancer, a prospective randomized trial is needed. Nevertheless, stereotactic body radiotherapy remains a suitable option for medically inoperable patients.
KW - SBRT
KW - carcinoma
KW - lobectomy
KW - lung cancer
KW - non–small cell
KW - radiosurgery
KW - radiotherapy
KW - recurrence
KW - stereotactic radiation
KW - surgery
KW - survival
KW - thoracoscopic lung resection
UR - http://www.scopus.com/inward/record.url?scp=85031032076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031032076&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2017.07.065
DO - 10.1016/j.jtcvs.2017.07.065
M3 - Article
C2 - 28888379
AN - SCOPUS:85031032076
SN - 0022-5223
VL - 155
SP - 395
EP - 402
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
IS - 1
ER -